Vaxxinity to Present at Upcoming Investor Conferences in September
CAPE CANAVERAL, Fla., Aug. 29, 2023 -- Vaxxinity, Inc. ; class='js-l-obf link link--blue'
Stay updated with breaking news from Mark Joinnides. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAPE CANAVERAL, Fla., Aug. 29, 2023 -- Vaxxinity, Inc. ; class='js-l-obf link link--blue'
Phase 2a data published in The Lancet’s eBioMedicinesupports further development of UB-311
CAPE CANAVERAL, Fla., Aug. 09, 2023 -- Vaxxinity, Inc. ; class='js-l-obf link link--blue'
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
Disease-modifying candidate UB-312 demonstrated target engagement of aggregated alpha-synuclein in cerebrospinal fluid of Parkinson’s patients Data provide validation of the Vaxxinity platform’s...